Money

Found 79,915 articles

• Artelon, Inc. Secures $20M in Funding to Advance Surgical Treatment of Joint Instability

  5/24/2023

  Artelon Inc., a privately held medical device company, announced that it closed approximately $20 million in Series B funding, led by Vensana Capital with expected additional participation from existing investors.

• Kineta Set to Join Russell Microcap® Index

  5/24/2023

  Kineta, Inc. announced that the company is set to join the Russell Microcap® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, 2023, according to a preliminary list of additions posted on May 19, 2023.

• Pluton Biosciences Raises $16.5M Series A led by Illumina Ventures and RA Capital to discover and deploy microbes that will fight climate change

  5/24/2023

  Pluton Biosciences, a startup leveraging the power of microbes to create cost-effective innovative solutions that address sustainability challenges facing agriculture, announces the close of a $16.5 M Series A funding round.

• Microbot Medical Announces Closing of $2.66 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

  5/24/2023

  Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,209,500 shares of the Company’s common stock (or common stock equivalents) at a purchase price of $2.20 per share of common stock priced at-the-market under Nasdaq rules.

• AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients

  5/24/2023

  AbCellera (Nasdaq: ABCL) today announced a CA$701 million co-investment with the Governments of Canada and British Columbia to build new capabilities and infrastructure to develop innovative antibody-based medicines and strengthen Canada’s leadership in clinical research, manufacturing, and drug development.

• 

  ReNAgade Launches with $300M to More Easily Deliver RNA Medicines

  5/23/2023

  The Massachusetts-based startup’s goal is to develop RNA medicines that can treat diseases anywhere in the body using an “all-in-one” platform.

• Athersys Restructures Debt with Supplier

  5/23/2023

  Athersys, Inc., a regenerative medicine company developing MultiStem® cell therapy for critical care indications announced it has restructured its outstanding debt with a supplier.

• Aphios Awarded NIH Grant For Development of a Double-Encapsulated mRNA Vaccine for COVID-19 and Other Diseases

  5/23/2023

  Aphios announced today that it was awarded an NIH grant to develop a double encapsulated mRNA vaccine for COVID-19 and other diseases.

• OnKure Therapeutics Announces $54 Million Series C Financing

  5/23/2023

  OnKure, Inc. a precision oncology company, today announced that it has successfully closed a $54 million Series C financing.

• Indivior PLC Form 20-F Registration Statement for Additional US Listing Now Available; Trading on NASDAQ Expected to Commence on June 12th

  5/23/2023

  Indivior PLC announced that its registration statement on Form 20-F required for the additional U.S. listing of its ordinary shares is now available at www.sec.gov and under the "Investors" section of the Company's website.

• Echo® MS Center of Excellence Launches at SCIEX Headquarters

  5/23/2023

  SCIEX, a global leader in life science analytical technologies, celebrates the opening of the Echo® MS Center of Excellence.

• Propanc Biopharma Announces Reverse Stock Split - May 23, 2023

  5/23/2023

  Propanc Biopharma, Inc., a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced that the Company’s board of directors has approved a reverse stock split of its common stock at a ratio of 1 post-split share for every 1,000 pre-split shares.

• Guardant Health Announces Pricing of Upsized Public Offering of Common Stock - May 23, 2023

  5/23/2023

  Guardant Health, Inc., a leading precision oncology company, announced the pricing of an upsized underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $28.00 per share, before deducting underwriting discounts and commissions.

• Agile Therapeutics Announces Pricing of $7.5 Million Public Offering

  5/23/2023

  Agile Therapeutics, Inc., a women's healthcare company, announced the pricing of its public offering of an aggregate of 1,896,286 shares of its common stock, together with accompanying common stock warrants, at a public offering price of $3.9551 per share and accompanying warrants.

• Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock - May 23, 2023

  5/23/2023

  Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced the pricing of its underwritten public offering of 11,125,000 shares of its common stock at a price to the public of $11.75 per share.

• Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock

  5/23/2023

  Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

• Protalix BioTherapeutics set to join Russell 3000® Index

  5/23/2023

  Protalix BioTherapeutics, Inc. announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, 2023 according to a preliminary list of additions posted May 19.

• Larkspur Biosciences Launches with $35.5 Million in Financing to Build the Next Precision Immunotherapies to Outsmart Cancer

  5/23/2023

  Larkspur Biosciences, a biotechnology company building the next precision immunotherapies to outsmart cancer, launched with $35.5 million in combined seed and Series A financing.

• Ocugen, Inc. Announces Proposed Public Offering of Common Stock - May 23, 2023

  5/23/2023

  Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, announced that it has commenced an underwritten public offering of its common stock.

• smartbax Announces Seed Financing of €1.2 Million to Develop Next-generation Antibiotics

  5/23/2023

  smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, announced the close of its seed financing round of €1.2 million from Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds, bringing smartbax’s total capital raised to €1.9 million.